'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Kopran Limited
KOPRAN (NSE) · KOPRAN (BSE 524280) · ISIN INE082A01010 · Pharmaceuticals · Est. 1958 · listed 1999 · website
Not on any surveillance list
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹62.76 cr and profit after tax ₹6.72 cr. Revenue was 22.3% higher than in Q1 FY26.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹62.76 cr | ₹6.72 cr | 1.39 | 7 Aug 2026 |
| Q4 FY26 standalone | ₹118.04 cr | ₹18.74 cr | 3.88 | 19 May 2026 |
| Q3 FY26 standalone | ₹93.88 cr | ₹12.13 cr | 2.51 | 22 Jan 2026 |
| Q2 FY26 standalone | ₹42.39 cr | −₹3.99 cr | −0.83 | 12 Nov 2025 |
| Q1 FY26 standalone | ₹51.33 cr | ₹3.52 cr | 0.73 | 29 Jul 2025 |
| Q4 FY25 standalone | ₹75.94 cr | ₹8.6 cr | 1.78 | 23 May 2025 |
| Q3 FY25 standalone | ₹195.07 cr | ₹18.26 cr | 3.78 | 12 Feb 2025 |
| Q2 FY25 standalone | ₹123.14 cr | ₹10.85 cr | 2.24 | 13 Nov 2024 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹447.83 cr | ₹46.36 cr | ₹605.89 cr |
| 30 Sep 2025 standalone | ₹416.28 cr | ₹45.83 cr | ₹525.67 cr |
| 31 Mar 2025 standalone | ₹431.44 cr | ₹45.31 cr | ₹546.48 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 41.82% | 0.91% | 0.00% | 58.18% |
Latest filings
- Kopran Limited has informed the Exchange about Investor Presentation 7 August 2026 · NSE
- Kopran Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. 7 August 2026 · NSE
- Annual Report FY2025-26 (New) 25 July 2026 · NSE
- Kopran Limited has informed the Exchange about Investor Presentation 20 May 2026 · NSE
- Kopran Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. 19 May 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Aurobindo Pharma Limited
- Divi's Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.